The purpose of this meta-analysis was to provide clinical evidence regarding relationship between ADC and cellularity in different tumors based on large patient data. Medline library was screened for associations between ADC and cell count in different tumors up to September 2016. Only publications in English were extracted. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) was used for the research. Overall, 39 publications with 1530 patients were included into the analysis. The following data were extracted from the literature: authors, year of publication, number of patients, tumor type, and correlation coefficients. The pooled correlation coefficient for all studies was ρ = -0.56 (95 % CI = [-0.62; -0.50]),. Correlation coefficients ranged from ρ =-0.25 (95 % CI = [-0.63; 0.12]) in lymphoma to ρ=-0.66 (95 % CI = [-0.85; -0.47]) in glioma. Other coefficients were as follows: ovarian cancer, ρ = -0.64 (95% CI = [-0.76; -0.52]); lung cancer, ρ = -0.63 (95 % CI = [-0.78; -0.48]); uterine cervical cancer, ρ = -0.57 (95 % CI = [-0.80; -0.34]); prostatic cancer, ρ = -0.56 (95 % CI = [-0.69; -0.42]); renal cell carcinoma, ρ = -0.53 (95 % CI = [-0.93; -0.13]); head and neck squamous cell carcinoma, ρ = -0.53 (95 % CI = [-0.74; -0.32]); breast cancer, ρ = -0.48 (95 % CI = [-0.74; -0.23]); and meningioma, ρ = -0.45 (95 % CI = [-0.73; -0.17]).